tirzepatide in hfpef At #ACC25, Dr. Milton Packer and colleagues present a new secondary analysis from the SUMMIT trial evaluating the effect of patients with obesity, #HFpEF, and CKD. The trial demonstrated that # Therapy for HFpEF: A step

Critical Research Limitation: Despite extensive preclinical and limited early-phase human studies, the CJC-1295 (NO DAC) + Ipamorelin blend peptide has NO completed, peer-reviewed Phase III clinical trials establishing human safety and efficacy for any medical indication

Two of the most advanced prescription medications approved for chronic weight management are Zepbound and Wegovy

Noticing issues can help make quick changes

In a Phase II study reported in 2024 involving 168 patients with NASH, moderate to advanced fibrosis (F2F3), and NAS 4, a significantly greater proportion of patients in the denifanstat group achieved the primary endpoint compared with placebo, with statistically meaningful improvements in fibrosis as well

Always review your plan documents or contact UMR directly for the most accurate and up-to-date information about your specific coverage

Cancel or pause whenever you want.